This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bunn, P. A. Articles by Jewett, P. B. Search for Related Content PubMed PubMed Citation Articles by Bunn, P. A., Jr. Articles by Jewett, P. B.

Neuropeptide Signal Transduction in Lung Cancer: Clinical Implications of Bradykinin Sensitivity and Overall Heterogeneity¹

Division of Medical Oncology and Department of Medicine, University of Colorado Cancer Center, Denver, Colorado 80262

To define the role of neuropeptides in lung cancer biology, we evaluated the effect of seven peptide classes on signal transduction and growth in human lung and breast cancer cell lines. Flow cytometric methods were used to quantitate the calcium response in individual cells produced by these peptides alone or in combination. The effects on growth were assessed by [³H]thymidine, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide, and soft agarose colony assays. All lung cancer cells demonstrated calcium responses to one or more peptides with classic small cell lines displaying the greatest responsiveness, followed by variant small cell lines and non-small cell lines. Breast cancer cell lines demonstrated little or no response. There was great variability in the magnitude of calcium response and pattern of response between lung cancer cell lines to individual neuropeptides. Bradykinin was the most potent peptide and produced responses in the highest fraction of lung cancer cell lines. Combinations of peptides produced greater intracellular calcium release than the single peptides, although in less than a quantitatively additive manner. Each peptide produced a refractory period which was peptide class specific. The growth stimulating effects of these neuropeptides were absent or small in magnitude and did not correlate with calcium signal transduction. These results imply that lung cancer cells display a wide sensitivity to neuropeptides but in a very heterogeneous manner. Knowledge of this heterogeneity should be incorporated into the design of antitumor strategies based on this autocrine pathway.

¹ Supported in part by Grants 1 U01 CA 46088-01 and 1 P30 CA 46934.

² To whom requests for reprints should be addressed, at University of Colorado Cancer Center, 4200 East 9th Avenue, Box B171, Denver, CO 80262.

Received 5/20/91. Accepted 10/17/91.

This article has been cited by other articles:

				L. M. F. Leeb-Lundberg, F. Marceau, W. Muller-Esterl, D. J. Pettibone, and B. L. Zuraw International Union of Pharmacology. XLV. Classification of the Kinin Receptor Family: from Molecular Mechanisms to Pathophysiological Consequences Pharmacol. Rev., March 1, 2005; 57(1): 27 - 77. [Abstract] [Full Text] [PDF]

				D. C. Chan, L. Gera, J. M. Stewart, B. Helfrich, T. L. Zhao, W. Y. Feng, K. K. Chan, J. M. Covey, and P. A. Bunn Jr. Bradykinin Antagonist Dimer, CU201, Inhibits the Growth of Human Lung Cancer Cell Lines in Vitro and in Vivo and Produces Synergistic Growth Inhibition in Combination with Other Antitumor Agents Clin. Cancer Res., May 1, 2002; 8(5): 1280 - 1287. [Abstract] [Full Text] [PDF]

				S. Clive, D. J. Webb, A. MacLellan, A. Young, B. Byrne, L. Robson, J. F. Smyth, and D. I. Jodrell Forearm Blood Flow and Local Responses to Peptide Vasodilators: A Novel Pharmacodynamic Measure in the Phase I Trial of Antagonist G, a Neuropeptide Growth Factor Antagonist Clin. Cancer Res., October 1, 2001; 7(10): 3071 - 3078. [Abstract] [Full Text] [PDF]

				L. E. Heasley, J. Zamarripa, B. Storey, B. Helfrich, F. M. Mitchell, P. A. Bunn Jr., and G. L. Johnson Discordant Signal Transduction and Growth Inhibition of Small Cell Lung Carcinomas Induced by Expression of GTPase-deficient Galpha[IMAGE] J. Biol. Chem., January 5, 1996; 271(1): 349 - 354. [Abstract] [Full Text] [PDF]